Search research articles
Contact Us
Filters
Showing results (91-100 of 111) with videos related to
Page
of 12
Sort By:
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
March 10, 2012
Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases
Rowena C Mercado, Heather Hampel, Fay Kastrinos, et al.
American Journal of Obstetrics and Gynecology
|
August 5, 2022
Less is more: clinical utility of postoperative laboratory testing following minimally invasive hysterectomy for endometrial cancer
Michelle D S Lightfoot, Ashley S Felix, Corinne A Calo, et al.
Gynecologic Oncology
|
April 10, 2023
Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes
Monica D Levine, David A Barrington, Caitlin E Meade, et al.
Gynecologic Oncology
|
May 27, 2026
Beyond extrapolation: Immunotherapy outcomes in recurrent vulvovaginal carcinoma
Cassidy S Abdeen, Reed M O'Connor, Julia Chalif, et al.
British Journal of Clinical Pharmacology
|
November 9, 2024
Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY
Mita Kuchimanchi, Trine Lembrecht Jørgensen, Eva Hanze, et al.
Cancer
|
November 20, 2016
What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study
Bunja J Rungruang, Austin Miller, Thomas C Krivak, et al.
Gynecologic Oncology
|
July 16, 2017
Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival
Casey M Cosgrove, David E Cohn, Heather Hampel, et al.
Gynecologic Oncology
|
September 23, 2017
Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study
Kathleen N Moore, David Tritchler, Kenneth M Kaufman, et al.
Gynecologic Oncology
|
March 9, 2025
Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278)
Jeanne Carter, Helen Q Huang, Bradley J Monk, et al.
Gynecologic Oncology
|
April 11, 2017
Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol
William T Creasman, Shamshad Ali, David G Mutch, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 111) with videos related to
Sort By:
Page
of 12
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
March 10, 2012
Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases
Rowena C Mercado, Heather Hampel, Fay Kastrinos, et al.
American Journal of Obstetrics and Gynecology
|
August 5, 2022
Less is more: clinical utility of postoperative laboratory testing following minimally invasive hysterectomy for endometrial cancer
Michelle D S Lightfoot, Ashley S Felix, Corinne A Calo, et al.
Gynecologic Oncology
|
April 10, 2023
Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes
Monica D Levine, David A Barrington, Caitlin E Meade, et al.
Gynecologic Oncology
|
May 27, 2026
Beyond extrapolation: Immunotherapy outcomes in recurrent vulvovaginal carcinoma
Cassidy S Abdeen, Reed M O'Connor, Julia Chalif, et al.
British Journal of Clinical Pharmacology
|
November 9, 2024
Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY
Mita Kuchimanchi, Trine Lembrecht Jørgensen, Eva Hanze, et al.
Cancer
|
November 20, 2016
What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study
Bunja J Rungruang, Austin Miller, Thomas C Krivak, et al.
Gynecologic Oncology
|
July 16, 2017
Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival
Casey M Cosgrove, David E Cohn, Heather Hampel, et al.
Gynecologic Oncology
|
September 23, 2017
Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study
Kathleen N Moore, David Tritchler, Kenneth M Kaufman, et al.
Gynecologic Oncology
|
March 9, 2025
Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278)
Jeanne Carter, Helen Q Huang, Bradley J Monk, et al.
Gynecologic Oncology
|
April 11, 2017
Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol
William T Creasman, Shamshad Ali, David G Mutch, et al.
Page
of 12